Publications by authors named "BenKang Shi"

Purpose: F-DCFPyL (targeted PSMA) and F-FDG dual-tracer PET/CT combination with next-generation sequencing was applied in a prospective cohort of men with prostate cancer to identify the clinical and genetic characteristics with heterogeneous PET/CT imaging features.

Methods: 104 men with documented prostate cancer underwent F-DCFPyL and F-FDG PET/CT, of which 83 underwent next-generation sequencing for detecting variation of AR, TP53, RB1, PTEN, etc. Lesions were classified into DCFPyL+FDG± lesions and DCFPyL-FDG+ lesions and analyzed for heterogeneous distribution.

View Article and Find Full Text PDF

Background: At present, there is no effective prognostic indicator for muscle invasive bladder cancer (MIBC). A liquid biopsy method, plasma circulating tumor DNA (ctDNA) detection, was evaluated for use in predicting the prognosis of different cancers. This study aims to assess the prognostic value of ctDNA state for muscle-invasive bladder cancer patients.

View Article and Find Full Text PDF

Nanomedicine-based photothermal therapy (PTT) has been considered as an excellent alternative for treatment of tumor tissue due to its high therapeutic efficiency and controllable range. However, the overexpression of heat shock proteins (HSPs) during PTT and the hypoxic properties of the tumor microenvironment can lead to intracellular thermal resistance and reduce its effectiveness. Reactive oxygen species (ROS), followed by the application of chemodynamic therapy (CDT) and photodynamic therapy (PDT), can eliminate HSPs and overcome thermal resistance.

View Article and Find Full Text PDF
Article Synopsis
  • The CHART trial explored the relationship between prostate-specific antigen (PSA) levels and survival outcomes in patients with high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC), involving 654 participants divided between two treatment groups.
  • Patients taking rezvilutamide plus androgen deprivation therapy (ADT) had significantly better PSA reductions (≥50% PSA reduction at 98.2% versus 87.5% and ≥90% reduction at 88.7% versus 63.1%) compared to those on bicalutamide plus ADT, indicating it may be more effective in delaying PSA progression.
  • Achieving undetectable PSA levels and ≥90% PSA reduction with rezvilutamide was linked to
View Article and Find Full Text PDF

Calcitonin gene-related peptide (CGRP), a neuropeptide involved in nociceptor neuronal function, plays a critical role in mediating neuroinflammation and pain. In this study, we find that bladder group 2 innate lymphoid cells (ILC2s) function as primary producers of CGRP in the early phase of bacterial cystitis, contributing to increased inflammation, altered voiding behavior, and heightened pelvic allodynia. Furthermore, we demonstrate that interleukin (IL)-33, a cytokine secreted by urothelial cells, upregulates CGRP production by ILC2s in the bladder during uropathogenic Escherichia coli (UPEC) infection.

View Article and Find Full Text PDF

Aim: Sacral neuromodulation (SNM) is widely recognized as the essential treatment modality for patients suffering from various lower urinary tract disorders, particularly overactive bladder (OAB). This prospective study recruited patients who underwent variable frequency SNM treatment at six Chinese medical centers, aiming to evaluate the gender-specific effects of this intervention and provide precise guidance on its application for clinical management.

Methods: This prospective study was managed by Beijing Hospital, and six Chinese medical centers participated in this prospective research.

View Article and Find Full Text PDF
Article Synopsis
  • The study explores the effect of sacral neuromodulation (SNM) on bladder dysfunction in rats with spinal cord injury, focusing on its mechanism during the bladder-areflexia phase.
  • It uses various methods like physiological measurements, staining techniques, and urodynamic tests to assess SNM's impact on bladder health and inflammation.
  • Results indicate that early SNM enhances bladder capacity and efficiency while preventing urothelial edema, suggesting potential therapeutic benefits for neurogenic bladder dysfunction without major adverse effects.
View Article and Find Full Text PDF

Data on prevalence of programmed death ligand-1 (PD-L1) expression and its correlation with tumor biomarkers in Chinese patients with muscle-invasive urothelial bladder cancer (MIUBC) are scarce. We investigated the prevalence of PD-L1 expression, PD-L1 expression in tumor cells (TC) and immune cells (IC), and its correlation with tumor biomarkers (CD8+ T cells and tumor mutation burden [TMB]) in Chinese patients with newly diagnosed MIUBC (NCT03433924). Of 248 patients enrolled, 229 with PD-L1 data available were analysed.

View Article and Find Full Text PDF

Background: MRG002 is a novel HER2-targeted antibody-drug conjugate being investigated in the MRG002-006 trial to evaluate the efficacy and safety in HER2-positive urothelial carcinoma patients.

Methods: This is an open-label, single-arm, multicenter phase II study. Eligibility criteria included: histologically confirmed HER2 IHC 2 + or 3 + UC, prior received ≥ 1 standard treatment.

View Article and Find Full Text PDF

The immune landscape of bladder cancer progression is not fully understood, and effective therapies are lacking in advanced bladder cancer. Here, we visualized that bladder cancer cells recruited neutrophils by secreting interleukin-8 (IL-8); in turn, neutrophils played dual functions in bladder cancer, including hepatocyte growth factor (HGF) release and CCL3PD-L1 super-immunosuppressive subset formation. Mechanistically, c-Fos was identified as the mediator of HGF up-regulating IL-8 transcription in bladder cancer cells, which was central to the positive feedback of neutrophil recruitment.

View Article and Find Full Text PDF

Background: CDC6 is an oncogenic protein whose expression level fluctuates during the cell cycle. Although several E3 ubiquitin ligases responsible for the ubiquitin-mediated proteolysis of CDC6 have been identified, the deubiquitination pathway for CDC6 has not been investigated.

Methods: The proteome-wide deubiquitinase (DUB) screening was used to identify the potential regulator of CDC6.

View Article and Find Full Text PDF

Purpose: Positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) targeting tracers has emerged as a valuable diagnostic tool for prostate cancer (PCa), androgen deprivation therapy (ADT) stands as the cornerstone treatment for advanced PCa, yet forecasting the response to hormonal therapy poses a significant clinical hurdle.

Methods: In a prospective cohort of 86 PCa patients undergoing short-term ADT, this study evaluated the prognostic potential of [18F]DCFPyL PET/CT scans. Comprehensive data encompassing clinical profiles, baseline prostate-specific antigen (PSA) levels, and imaging metrics were assessed.

View Article and Find Full Text PDF

Objective: To explore how prostate health index (PHI) and multiparametric magnetic resonance imaging (mpMRI) should be used in concert to improve diagnostic capacity for clinically significant prostate cancers (CsCaP) in patients with prostate-specific antigen (PSA) between 4 and 20 ng/ml.

Methods: About 426 patients fulfilling the inclusion criteria were included in this study. Univariable and multivariable logistic analyses were performed to analyze the association between the clinical indicators and CaP/CsCaP.

View Article and Find Full Text PDF

To evaluate the effects of neoadjuvant vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI) treatment on surgery in patients with renal cell carcinoma (RCC), sources from Embase, PubMed and the Cochrane Library databases collected from inception to December, 2022 were used for analysis in the present study, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Data regarding surgical outcomes were collected. The pooled effect sizes were calculated in terms of the risk ratio (RR)/standard mean difference (SMD) with 95% confidence intervals (CIs) using the random-effects model.

View Article and Find Full Text PDF

Objective: Real-word data on long-acting luteinizing hormone-releasing hormone (LHRH) agonists in Chinese patients with prostate cancer are limited. This study aimed to determine the real-world effectiveness and safety of the LHRH agonist, goserelin, particularly the long-acting 10.8-mg depot formulation, and the follow-up patterns among Chinese prostate cancer patients.

View Article and Find Full Text PDF

Background: PSMA-negative but FDG-positive (PSMA-/FDG+) lesion in dual-tracer (Ga-PSMA and F-FDG) positron emission tomography/computed tomography (PET/CT) is associated with an unfavorable response to Lutetium-177 (Lu)-PSMA-617. This study sought to develop both radiomics and clinical models for the precise prediction of the presence of PSMA-/FDG+ lesions in patients with castration-resistant prostate cancer (CPRC).

Methods: A cohort of 298 patients who underwent dual-tracer PET/CT with a less than 5-day interval was included.

View Article and Find Full Text PDF

Although hyperhomocysteinemia (hHcys) has been recognized as an important independent risk factor in the progression of end-stage renal disease and the development of cardiovascular complications related to end-stage renal disease, the mechanisms triggering pathogenic actions of hHcys are not fully understood. The present study was mainly designed to investigate the role of HDACs in renal injury induced by hHcys. Firstly, we identified the expression patterns of HDACs and found that, among zinc-dependent HDACs, HDAC9 was preferentially upregulated in the kidney from mice with hHcys.

View Article and Find Full Text PDF

Purpose: To evaluate the efficacy and safety of disitamab vedotin (DV, RC48-ADC), a novel humanized anti-human epidermal growth factor receptor 2 (HER2) antibody conjugated with monomethyl auristatin E, in patients with HER2-positive locally advanced or metastatic urothelial carcinoma (UC) refractory to standard or regular therapies.

Patients And Methods: The data analyzed and reported are from two phase II, open-label, multicenter, single-arm studies (RC48-C005 and RC48-C009) in patients with HER2-positive (immunohistochemistry 3+ or 2+) locally advanced or metastatic UC who have progressed on at least one previous line of systemic chemotherapy. Patients received DV treatment (2 mg/kg IV infusion, once every 2 weeks).

View Article and Find Full Text PDF

The vascular and morphological features of tumors are important predictors of the nature, grade, and stage of various cancers. However, this association has not been tested in bladder cancer. The aim of our study was to investigate the correlation between the morphological characteristics of tumor vessels and the nature, stage and grade of bladder cancer.

View Article and Find Full Text PDF

Purpose: To investigate the difference in gut microbiome composition between patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and healthy controls, and to assess the potential of gut microbiota as predictive markers for CP/CPPS risk.

Methods: The present study included 41 CP/CPPS patients and 43 healthy controls in China. Fecal specimen data were obtained and analysed using 16S rRNA gene sequencing.

View Article and Find Full Text PDF

Purpose: At present, the prediction of bladder tumor nature during cystoscopy is partially dependent on the clinician's own experience. Subjective factors may lead to excessive biopsy or delayed treatment. The purpose of our study is to establish a reliable model for predicting the nature of bladder tumors using narrow band imaging.

View Article and Find Full Text PDF

There is significant variability with respect to the prognosis of nonmetastatic clear cell renal cell carcinoma (ccRCC) patients with venous tumor thrombus (VTT). By applying multiregion whole-exome sequencing on normal-tumor-thrombus-metastasis quadruples from 33 ccRCC patients, we showed that metastases were mainly seeded by VTT (81.8%) rather than primary tumors (PTs).

View Article and Find Full Text PDF
Article Synopsis
  • This research aims to enhance the understanding of clear-cell renal cell carcinoma (ccRCC) with venous tumor thrombus (VTT) to better select candidates for additional therapy based on their recurrence risk.
  • The study retrospectively analyzed data from 604 patients with nonmetastatic ccRCC, finding that discrepancies in tumor grade between the primary tumor and VTT significantly influenced disease-free survival (DFS), overall survival (OS), and cancer-specific survival (CSS).
  • Incorporating tumor grade discrepancy into predictive models improved their accuracy, indicating that this information can lead to more personalized and effective treatment strategies for patients.
View Article and Find Full Text PDF

Background: Bladder cancer is the ninth most common malignant tumor worldwide. As an effective evidence-based multidisciplinary protocol, the enhanced recovery after surgery (ERAS) program is practiced in many surgical disciplines. However, the function of ERAS after radical cystectomy remains controversial.

View Article and Find Full Text PDF